Commercial Alamar, Hemab, Kailera, and Seaport advance IPOs PharmaphorumThe last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.CommercialRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings. CommercialRead full story Post navigation Previous: Spyre drug for inflammatory bowel disease shows promise in early studyNext: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026